Phase I study of JAK1/2 inhibitor ruxolitinib with weekly paclitaxel for the treatment of HER2-negative metastatic breast cancer.
Filipa C LynceJames T WilliamsMeredith M ReganCraig A BunnellRachel A FreedmanSara M TolaneyWendy Y ChenErica L MayerAnn H PartridgeEric P WinerBeth OvermoyerPublished in: Cancer chemotherapy and pharmacology (2021)
NCT02041429. Date of registration: January 22, 2014.